![](https://investorshub.advfn.com/uicon/276021.png?cb=1471598439)
Wednesday, September 28, 2011 9:48:23 AM
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, was pleased to announce today the issuance of two additional United States patents supporting its therapeutic and drug discovery programs.
U.S. Patent 7,763,466, titled “Mesoderm and Definitive Endoderm Cell Populations,” and U.S. Patent 7,955,849, titled “Method of Enriching a Mammalian Cell Population for Mesoderm Cells,” further enhance VistaGen’s intellectual property portfolio and provide additional protection for its proprietary research and development activities. Methods covered in these important new U.S. patents describe the use of activin and serum-free culture conditions for producing endoderm and mesoderm.
“Strong and enforceable intellectual property rights are critical components of our plan to optimize the commercial potential of our Human Clinical Trials in a Test Tube™ platform,” said Shawn K. Singh, VistaGen’s Chief Executive Officer. “These patents further solidify our growing IP portfolio. Generally speaking, they expand the application of our activin-driven pluripotent stem cell differentiation technology to include a broader range of tissues and organ systems, and significantly strengthen our market position.”
Mesoderm and endoderm are two of the three primary early precursors, “germ layers,” which develop into all of the non-neuronal cells of the body. Endoderm is the innermost of the three primary developmental germ layers, and develops into the gastrointestinal tract, including the major cells of the liver and pancreas, respiratory tracts of the lungs, other endocrine glands and organs, such as the thyroid and thymus glands, the major cells of the kidney and the auditory and urinary systems. Mesoderm is the germ layer lying adjacent to the endoderm. These multi-potential cells develop into cardiac and skeletal muscles, all the cells of blood and lymphatic systems, bone, cartilage, fat, the lining of blood vessels, and connective tissues.
Activins are members of the important transforming growth factor beta (TGF-beta) family of “morphogens,” i.e. developmental factors that direct and control the differentiation and eventual fate of early precursor cells. During development, the body uses differing concentrations of morphogens, similar to activin, to direct precursors to become the various mature cells discussed above. Methods utilizing differing concentrations of activin to direct and control the differentiation of various mature cell types are described in these issued U.S. patents and are widely-believed as having significant commercial value.
In addition to the patent estate that VistaGen owns and controls by license in the U.S., the Company has proprietary rights to a large and growing number of patents granted in territories outside the U.S. Having recently reported its original research demonstrating the use of pluripotent stem cells to generate insulin, these issued U.S. patents further highlight VistaGen’s leadership position in the field as the Company applies its Human Clinical Trials in a Test Tube™ platform for proprietary applications in drug rescue, cell therapy and regenerative medicine.
The patent families related to these two issued patents are subject to exclusive licenses to VistaGen on a worldwide basis through an agreement with Mount Sinai School of Medicine (MSSM) in New York. The patents stem from work conducted by scientists in the laboratory of Dr. Gordon Keller, formerly a Professor of Gene and Cell Medicine at MSSM and Director of its Black Family Stem Cell Institute. Dr. Keller is now Director of the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Chairman of VistaGen’s Scientific Advisory Board.
Recent VTGN News
- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine • Business Wire • 07/09/2024 12:30:00 PM
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM